VANCOUVER, June 14, 2017 /PRNewswire/ - Isodiol International Inc.- (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the "Company" or "Isodiol")a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce we are one of the key sponsors at the NY Cannabis World Congress & Business Expo this June 14-16.
"Isodiol is also honored to have Dr. Ron Aung-Din, a neurologist with over 35 years of experience in General Neurology and Neuro-Psychiatry, speaking about the positive benefits and advancements of phytocannabinoids and presenting IsoDerm, a premium product he developed along with the team at Isodiol," said Isodiol's CEO Marcos Agramont.
"Sponsoring this event along with having Dr. Ron Aung-Din present at the seminar, gives Isodiol key exposer to play an active roll in our industry and meet with global vendors and investors to speak firsthand with them about what we believe, which is, we are at the start of significant global operational highlights that will give our company a very strong foundation for customer engagement and retention, while accelerating Isodiol's pace of innovation and competitive differentiation moving forward, with our brands like CBD Naturals, Iso-Sport, CannaCeuticals CBD Skincream, and Pot-O-Coffee," said Agramont.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"CEO & Director
Join Us On Face Book:https://www.facebook.com/isodiol/
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE Isodiol International Inc.
Subscribe to our Free Newsletters!
Adrenalectomy is a surgery that involves removing either one or both the adrenal glands.
Craniosynostosis is a condition where the bones of the skull are fused together prematurely ...
Episiotomy is a surgical incision made in the perineum between the vaginal orifice and the anus ...View All